Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials in lebrikizumab clinical trial program
Safety profile consistent with prior lebrikizumab studies ... Biopharmaceuticals, Dermatology Eli Lilly, lebrikizumab, atopic dermatitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Dermatitis | Dermatology | Itchiness | Pharmaceuticals | Skin | Sleep Disorders | Sleep Medicine | Study